Edited by: Thomas Bieber
Registration trials for specific immunotherapy in Europe: advanced guidance from the new European Medical Agency guideline
Article first published online: 29 OCT 2010
© 2010 John Wiley & Sons A/S
Volume 65, Issue 12, pages 1499–1505, December 2010
How to Cite
Gödicke, V. and Hundt, F. (2010), Registration trials for specific immunotherapy in Europe: advanced guidance from the new European Medical Agency guideline. Allergy, 65: 1499–1505. doi: 10.1111/j.1398-9995.2010.02436.x
- Issue published online: 29 OCT 2010
- Article first published online: 29 OCT 2010
- Accepted for publication 1 June 2010
- allergen products;
- clinical trials;
- regulatory affairs
To cite this article: Gödicke V, Hundt F. Registration trials for specific immunotherapy in Europe: advanced guidance from the new European Medical Agency guideline. Allergy 2010; 65: 1499–1505.
Marketing authorization of medicinal products is granted based on results of registration trials. The European Medical Agency (EMA) has issued general and disease state-specific guidelines for the conduct of such trials. In the area of allergic diseases, there are basically two general therapeutic approaches: Drugs that mitigate the symptoms and an approach that is targeted to the root cause of the disease, the allergen-specific immunotherapy (SIT). While the ‘Guideline on the Clinical Development of Medicinal Products for the Treatment of Allergic Rhino-Conjunctivitis’ (CHMP/EWP/2455/02) and the ‘Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Asthma’ (CPMP/EWP/2922/01) focuses exclusively on the development of medicinal products to treat allergic symptoms, there was no guideline for SIT in the past. In consequence, the conduct of clinical trials for SIT was widely lacking a standardized approach. This created difficulties when comparing drugs and outcomes and also uncertainty to predict marketing authorization. In 2009, the EMA has issued a new guideline on the clinical development of products for SIT. Despite some white spots in some areas, the new guideline constitutes a breakthrough with regard to guidance, harmonization and transparency in the conduct of clinical trials in SIT.